PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
Abstract
Authors
P. Hari A. Nguyen C. Pelletier K. Hege N. McGarvey M. Gitlin K. Parikh